Daiichi Sankyo Company, LimitedTSE: 4568

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

· Issued by Daiichi Sankyo Company, Limited

On 6ix: 6ix.com/news/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-summit-therapeutics-to-evaluate-datrowayr-in-combination-with-ivonescimab-across-multiple-tumor-types

Watch Daiichi Sankyo's latest callDaiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call · Replay · Jul 31Read the transcript of Daiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types Tokyo - (October 2, 2026) - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Daiichi Sankyo Company, Limited on 6ix

Story so far

Earlier from Daiichi Sankyo

Later from Daiichi Sankyo

All Daiichi Sankyo news releases